IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: contrarian who wrote (1307)	10/12/1997 2:22:00 AM
From: Roger Cranwill	of 1762

Wow-rate the importance of this drug.....I don't really anyone can yet tell the full implications of this drug yet. It will be the only drug indicated for Non-Hodgkins lymphoma-no course of chemo carries the express consent for use by the FDA-I think that in itself will be a strong factor for its becoming a major player with chemo. Also, with chemo, each successive relapse of the disease is fought less effectively by chemo, causing higher doses,with higher toxicity and side effects. The people who have gone into remission with C2B8 are still in remission (to my knowledge), so the full implications of this drug are yet to be reached. In importance, probably not up there with the Salk vaccine, but definitely a milestone of major import-A new way of fighting disease-not using foreign agents in the body to effect an outcome, but harnessing the patients own immune system by targeting specific cells. There are other guys much more sophisticated than I on this thread who can probably do a better job of explanation, but this is the way I see it. Roger

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next